Now that we are in the heat of summer the books have closed for the first half of the year. Here in the exclusive piece for our subscribers in which our team will individually reflect on our first … [Read more...] about MS Conference Call Exclusive: Reflecting on the 1st Half of 2019
MS Performance Tracker Showing Data From Friday June 14th After The Market Closed Two weeks into June the markets are continuing to recover from the painful volatility we experienced in April and … [Read more...] about Biopharma Stock Watch June 17th-21st
May 27th-31st we saw a continuation of brutal market volatility spurred by an escalating trade war with china, new tariffs, and rhetoric of war with Iran. Trade negotiations earlier this month ended … [Read more...] about Biopharma Stock Watch June 3rd-7th
The consumer trap is an idea suggesting that a capitalist economy systematically imprisons the majority of middle and lower class families by edging them into accruing debt through having to keep up … [Read more...] about The Consumer Trap and How to Avoid it.
An IRA, or Individual Retirement Account, is a retirement plan offered by financial institutions. In an IRA, all the money that you choose to contribute is tax-deductible, meaning you don't have to … [Read more...] about What is an IRA?
Overview We have recently begun releasing educational pieces on technical strategies. The most recent article covering RSI got us thinking about other useful indicators for the less seasoned … [Read more...] about Moving Averages; SMA & EMA Explained
Overview Wednesday October 24th, 2018 the stock market was slashed across the board with the DOW erasing all its gains for the year and dripping red. The Nasdaq was hit with equal force. Comments from … [Read more...] about Potentially Lucrative Opportunities Amidst A Stock Market Bloodbath
GALT’s phase 3 study inclusion criteria will be patients diagnosed with NASH-cirrhosis but without varices, and includes an interim analysis. Competition in the NASH-cirrhosis space is lacking. The … [Read more...] about Galectin Blocker is Front Runner in Fight Against NASH-Cirrhosis
For months Verastem Oncology (VSTM) investors have been eagerly awaiting the FDA's decision on it's lead product Duvelisib; a PI3K-δ (delta) and PI3K-γ (gamma) inhibitor that was granted Orphan Drug … [Read more...] about VSTM Overaction to Black Box Label Creates Buying Opportunity
On August 27th, 2018 MS Money Moves initiated coverage on Adamis Pharmaceuticals (ADMP). At the time it was trading at $2.85 per share. Our analysis of the company indicated that it was oversold and … [Read more...] about ADMP Poised For NDA Approval